论文信息 - Post‐COVID‐19 Myoclonus‐Ataxia Syndrome—Is there Really a Need for Intravenous Immunoglobulin Treatment in all Cases? - 字舞流文

Post‐COVID‐19 Myoclonus‐Ataxia Syndrome—Is there Really a Need for Intravenous Immunoglobulin Treatment in all Cases?

We have read

J. Sławek | Filip Przytuła

[1] G. Lanza,et al. Post–COVID‐19 Myoclonus–Ataxia Syndrome Responsive to Intravenous Immunoglobulins , 2022, Movement disorders clinical practice.

[2] A. Słowik,et al. Acute-onset chorea and confusional state in 77-year-old COVID-19 patient: a case report. , 2022, Neurologia i neurochirurgia polska.

[3] S. Schneider,et al. Relationship between COVID‐19 and movement disorders: A narrative review , 2021, European journal of neurology.

[4] A. Hirschfeld. Autoimmune mediated hyperkinetic movement disorders in SARS-CoV-2 infection - a systematic review. , 2021, Neurologia i neurochirurgia polska.

[5] J. Sławek,et al. Two COVID-19-related video-accompanied cases of severe ataxia-myoclonus syndrome. , 2021, Neurologia i neurochirurgia polska.